Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc on October 22, 2025. The filing addresses a significant change in executive leadership, specifically the appointment of an interim Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and the associated compensation agreement.
Material Changes
The primary material change reported is the appointment of Kameel Farag as Interim Chief Financial Officer, effective October 22, 2025. Mr. Farag succeeds Torsten Hombeck, whose departure was previously reported. Mr. Farag will serve in this interim capacity until a permanent successor is qualified and appointed.
Management Commentary and Compensation Arrangements
In connection with his appointment, the Company entered into a Consulting Agreement with Mr. Farag and KDF Ventures LLC. The compensation structure is as follows:
- Through December 31, 2025: Monthly fee of $18,000 in cash plus $12,000 in Restricted Stock Units (RSUs), vesting monthly.
- January 1, 2026 through February 15, 2026: Monthly fee increases to $27,000 in cash plus $13,000 in RSUs, vesting monthly.
- Capital Raise Incentives: KDF Ventures is entitled to additional compensation in cash and RSUs based on a percentage of gross proceeds from capital raises, subject to maximum limits.
- Term: The agreement ends on February 16, 2026, with an option for month-to-month extension at the Company's discretion.
Mr. Farag brings extensive experience from roles at Aspen Neuroscience, Ionis Pharmaceuticals, and Amgen, including overseeing financing and scaling operations.
Investor Verification Checklist
- Verify the full text of the Consulting Agreement filed as Exhibit 10.1 to understand specific terms regarding capital raise incentives and termination clauses.
- Confirm the timeline for the search and appointment of a permanent Chief Financial Officer.
- Review subsequent filings for any updates on the Company's liquidity position or capital raise activities that may trigger the variable compensation clauses.